TrialCancer medicine2025

NEPA (Netupitant/Palonosetron) for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial.

Rudolph M Navari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.